LUMBY, B.C., July 10 /PRNewswire-FirstCall/ -- avVaa World Health Care
Products, Inc. (OTC Bulletin Board: AVVW), a biotech company offering
therapeutic skin and health care products to customers worldwide, is
pleased to announce positive findings from a number of scientific studies
leading the way to avVaa's next generation of NeuroSkin(TM) products.
avVaa Vice President of Research and Development, Dr. Mark Alden,
recently presented data from the first clinical trail demonstrating the
efficacy of patented nanoparticle silicic acid, the backbone of avVaa's
next generation of NeuroSkin products at the plenary session of the New
Jersey Technology Council Conference at Princeton University.
At the presentation, Dr. Alden explained the vital role that silicon
plays (in its biologically active amorphous form) in skin health and
resilience (collagen formation, moisture retention, wound healing, among
others). The conference, aimed at commercializing nanotechnology in the
life sciences, hosted speakers from around the world. Interested parties
may download a copy of the presentation materials at:
http://www.otcfn.com/avvw or http://www.avvaa.com.
The study, soon to be published, was conducted in Munich, Germany on
patients suffering from eczema -- for many, a lifelong affliction. Testing
both the mild and forte formulations, the study results were very positive.
After just four weeks' use of NeuroSkin, researchers noted a 59%
decrease in symptoms of erythema, a 70% reduction in skin scaling, a 63%
improvement in infiltration, and a 45% reduction in itching. No adverse
reactions were reported, and the products were well tolerated by the
patients studied: 100% considered the mild version pleasing, and 94% the
forte version (scent and irritation). Dr. Alden considered these results
"remarkable," and "ground breaking," for a product with no toxicity.
Two other studies using nanoparticle silicon were presented at the 42nd
National Dermatology Congress, in Rimini, Italy. One, conducted by C.
Rigoni, et. al. on children with eczema, and the other by S. Chimenti, et.
al. on adults with Psoriasis, showed strikingly similar results. The
percentage of patients experiencing greater than 50% reduction in symptoms
was 85% and 71% in the two studies, respectively. Ninety percent reported
an improvement in the quality of life index.
Unlike virtually all commonly prescribed treatments for eczema
(including steroids, UV light, coal tar, or chemotherapy), avVaa' NeuroSkin
formulation does not require treatment breaks or limited use, since there
are no known ill effects or toxicities. NeuroSkin contains silicic acid, a
silicon-containing molecule found to be safe for topical application,
backed by years of research.
Alden continued, "The incidence of common skin ailments is growing
worldwide. Yet, for the millions of people suffering from eczema and
psoriasis, no cure is in sight. The only current palliative treatments
available come with a risk of adverse effects, and their use must be
limited. avVaa World Health Care Products, using a patented process that
refines silica to nanoparticle size, provides a non-toxic solution for
patients suffering from this growing health problem.
"The results of these studies conducted around the world, together with
ongoing trials, support our current line, and lead the way to new products
under development -- including new applications and next generation
formulations of NeuroSkin, which we are very excited about."
avVaa CEO and Director Jack Farley said, "We are encouraged by recent
study findings on our newest product lines. Well-researched, controlled
scientific studies as to efficacy and safety lend substantial credibility
in the marketplace and we look forward to full introduction of these unique
skin care products that will meet avVaa's strictest standards for
non-toxic, therapeutic skin care products to improve quality of life and
well being for consumers worldwide."
About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that
specializes in effective, non-toxic, therapeutic skin care products that
improve quality of life and well being for consumers.
The Company's patented European skin care formulas are scientifically
registered, FDA-Compliant, and were developed to relieve and treat the
symptoms of common skin ailments, including: eczema, psoriasis and acne.
Many avVaa products are already available for over-the-counter purchase at:
avVaa is poised to manufacture and market its OTC NeuroSkin(TM) line of
skin care products through mass, food and drug channels in the United
States and globally. The Company's secondary line of equine and pet care
related products are already being distributed throughout all of Canada and
parts of the United States. For more information, visit:
http://www.avvaa.com or http://www.otcfn.com/avvw.
Contact: Merle Goertz (West Coast) of avVaa World Health Care Products,
1- 604-688-2349 or Rick McCaffrey at OTC Financial Network, Investor
Relations, 781-444-6100 x625.
Safe Harbor: Statements contained in this press release that are not
based upon current or historical fact are forward looking in nature. Such
forward- looking statements are subject to risks and uncertainties, which
could cause actual results to differ materially from estimated results.
Management cautions that all statements as to future results of operations
are necessarily subject to risks, uncertainties, and events that may be
beyond the control of avVaa World Health Care Products, Inc. and no
assurance can be given that such results will be achieved. Potential risks
and uncertainties include but are not limited to the ability to procure,
properly price, retain, and successfully complete projects, the
availability of technical personnel, changes in technology, and
SOURCE avVaa World Health Care Products, Inc.